These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17604880)

  • 1. Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine.
    Hepburn MJ; Hugh Dyson E; Simpson AJ; Brenneman KE; Bailey N; Wilkinson L; Hornby R; Mateczun AJ; Bell MG; Baillie LW
    Vaccine; 2007 Aug; 25(32):6089-97. PubMed ID: 17604880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
    Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
    Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
    Semenova VA; Schmidt DS; Taylor TH; Li H; Steward-Clark E; Soroka SD; Ballard MM; Quinn CP
    Vaccine; 2007 Feb; 25(10):1780-8. PubMed ID: 17229495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
    Dumas EK; Garman L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Choudhari S; Picking WD; James JA; Farris AD
    Vaccine; 2017 Jun; 35(26):3416-3422. PubMed ID: 28504191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
    Sloat BR; Cui Z
    J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine.
    Lininger LA; Cullum ME; Lyles MB; Bienek DR
    Vaccine; 2007 Feb; 25(9):1619-25. PubMed ID: 17150286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
    Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
    Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of an anthrax DNA vaccine with electroporation.
    Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R
    Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
    Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
    J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
    Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
    Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of anti-protective antigen salivary IgG antibodies in recipients of the US licensed anthrax vaccine.
    Bienek DR; Chang CK; Cohen ME
    Vaccine; 2007 Aug; 25(32):5978-84. PubMed ID: 17597265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.
    Pittman PR; Norris SL; Barrera Oro JG; Bedwell D; Cannon TL; McKee KT
    Vaccine; 2006 Apr; 24(17):3654-60. PubMed ID: 16497418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
    Sloat BR; Shaker DS; Le UM; Cui Z
    FEMS Immunol Med Microbiol; 2008 Mar; 52(2):169-79. PubMed ID: 18194342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women.
    Zhang Y; Martin SW; Rose CE; Biagini RE; Franzke LH; Smith JP; Sammons DL; Robertson SA; McNeil MM
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1060-7. PubMed ID: 18781705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid.
    Cui Z; Sloat BR
    Int J Pharm; 2006 Jul; 317(2):187-91. PubMed ID: 16730934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.
    Hewetson JF; Little SF; Ivins BE; Johnson WM; Pittman PR; Brown JE; Norris SL; Nielsen CJ
    Vaccine; 2008 Aug; 26(33):4262-6. PubMed ID: 18586363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.
    Klinman DM; Xie H; Little SF; Currie D; Ivins BE
    Vaccine; 2004 Jul; 22(21-22):2881-6. PubMed ID: 15246624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
    Gu M; Hine PM; James Jackson W; Giri L; Nabors GS
    Vaccine; 2007 Jan; 25(3):526-34. PubMed ID: 16973247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an in vitro-based potency assay for anthrax vaccine.
    Little SF; Webster WM; Ivins BE; Fellows PF; Norris SL; Andrews GP
    Vaccine; 2004 Jul; 22(21-22):2843-52. PubMed ID: 15246620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses.
    Dyson EH; Simpson AJH; Gwyther RJ; Cuthbertson H; Patient DH; Matheson M; Gregg A; Hepburn MJ; Hallis B; Williamson ED
    Vaccine; 2022 Oct; 40(42):6163-6178. PubMed ID: 36153153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.